The angiogenesis inhibitor thrombospondin-1 inhibits acute cutaneous hypersensitivity reactions

Journal of Investigative Dermatology

Volumn 129, Issue 8, 2009, Pages 2022-2030

  Velasco, Paula ^a   Huegel, Rainer ^a   Brasch, Jochen ^a   Schröder, Jens M ^a   Weichenthal, Michael ^a   Stockfleth, Eggert ^b   Schwarz, Thomas ^a   Lawler, Jack ^c   Detmar, Michael ^d   Lange Asschenfeldt, Bernhard ^a,b,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ETH ZURICH   (Switzerland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN ALLERGY; SKIN EDEMA; SKIN INFLAMMATION; UPREGULATION;

EID: 67651119741     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.447     Document Type: Article

References (46)

1. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L et al. (2002) Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16:267-9
2. Braverman IM, Sibley J (1982) Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 78:12-7
3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature407:249-57
4. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M et al.(2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-83
5. Cassatella MA (1999) Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol 73:369-509
6. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO et al. (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-70
7. Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E et al.(2000) Genes expressed in human tumor endothelium. Science289: 1197-202
8. Detmar M (2000) The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 24(Suppl 1):S78-84
9. DiPietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM, Polverini PJ (1996) Thrombospondin 1 synthesis and function in wound repair. Am J Pathol148:1851-60
10. Doyen V, Rubio M, Braun D, Nakajima T, Abe J, Saito H et al. (2003) Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med 198:1277-83
11. Enk AH, Katz SI (1995) Contact sensitivity as a model for T-cell activation in skin. J Invest Dermatol 105:80S-3S
12. Gad SC, Dunn BJ, Dobbs DW, Reilly C, Walsh RD (1986) Development and validation of an alternative dermal sensitization test: the mouse ear swelling test (MEST). Toxicol Appl Pharmacol 84:93-114
13. Good DJ, Polverini PJ, Rastinejad F, Le BM, Lemons RS, Frazier WA et al.(1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624-8
14. Harder J, Schroder JM (2002) RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem 277:46779-84
15. Hawighorst T, Oura H, Streit M, Janes L, Nguyen L, Brown LF et al. (2002) Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 21:7945-56
16. Huegel R, Velasco P, De la Luz Sierra M, Christophers E, Schroder JM, Schwarz T et al. (2007) Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin. J Invest Dermatol 127:65-74
17. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J11:457-65
18. Koch AE, Friedman J, Burrows JC, Haines GK, Bouck NP (1993) Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology 61:1-6
19. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P et al. (2004) Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104:1048-57
20. Lange-Asschenfeldt B, Weninger W, Velasco P, Kyriakides TR, von Andrian UH, Bornstein P et al. (2002) Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2-deficient mice. Blood 99:538-45
21. Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12
22. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H et al.(1998) Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982-92
23. Ludlow A, Yee KO, Lipman R, Bronson R, Weinreb P, Huang X et al. (2005) Characterization of integrin beta6 and thrombospondin-1 double-null mice. J Cell Mol Med 9:421-37
24. Meade R, Askenase PW, Geba GP, Neddermann K, Jacoby RO, Pasternak RD (1992) Transforming growth factor-beta 1 inhibits murine immediate and delayed type hypersensitivity. J Immunol 149:521-8
25. Motegi K, Harada K, Pazouki S, Baillie R, Schor AM (2002) Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. Histochem J 34:411-21
26. Oura H, Silva J, Velasco P, Brown LF, Carmeliet P, Detmar M (2002) A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 5:560-7
27. Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol165:2087-98
28. Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, Lawler JW et al. (2008) Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 75:9-21
29. Qian X, Rothman VL, Nicosia RF, Tuszynski GP (2001) Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res 7:251-9
30. Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF et al. (2007) Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. J Cell Physiol211:504-12
31. Riessen R, Kearney M, Lawler J, Isner JM (1998) Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J 135(2 Part 1):357-64
32. Sargiannidou I, Zhou J, Tuszynski GP (2001) The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 226:726-33
33. Savill J, Hogg N, Ren Y, Haslett C (1992) Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90:1513-22
34. Senger DR, Brown LF, Claffey KP, Dvorak HF (1994) Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis14:385-94
35. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K et al.(2001) Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 159:893-903
36. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L et al. (2000) Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 19:3272-82
37. Suchard SJ, Burton MJ, Dixit VM, Boxer LA (1991) Human neutrophil adherence to thrombospondin occurs through a CD11/CD18-independent mechanism. J Immunol 146:3945-52
38. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD et al.(1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-4
39. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N (1997) Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvascular Res54:13-26
40. Tuszynski GP, Nicosia RF (1996) The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays 18:71-6
41. Wight TN, Raugi GJ, Mumby SM, Bornstein P (1985) Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 33:295-302
42. Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A (1989) Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 86:612-6
43. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102:161-8
44. Yano K, Brown LF, Lawler J, Miyakawa T, Detmar M (2003) Thrombospondin- 1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. J Invest Dermatol120:14-9
45. Yano K, Oura H, Detmar M (2002) Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photodamage. J Invest Dermatol 118:800-5
46. Zhang J, Ito R, Oue N, Zhu X, Kitadai Y, Yoshida K et al. (2003) Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch 442:563-8